TY  - JOUR
AU  - Mackay, Alan
AU  - Burford, Anna
AU  - Molinari, Valeria
AU  - Jones, David
AU  - Izquierdo, Elisa
AU  - Brouwer-Visser, Jurriaan
AU  - Giangaspero, Felice
AU  - Haberler, Christine
AU  - Pietsch, Torsten
AU  - Jacques, Thomas S
AU  - Figarella-Branger, Dominique
AU  - Rodriguez, Daniel
AU  - Morgan, Paul S
AU  - Raman, Pichai
AU  - Waanders, Angela J
AU  - Resnick, Adam C
AU  - Massimino, Maura
AU  - Garrè, Maria Luisa
AU  - Smith, Helen
AU  - Capper, David
AU  - Pfister, Stefan
AU  - Würdinger, Thomas
AU  - Tam, Rachel
AU  - Garcia, Josep
AU  - Thakur, Meghna Das
AU  - Vassal, Gilles
AU  - Grill, Jacques
AU  - Jaspan, Tim
AU  - Varlet, Pascale
AU  - Jones, Chris
TI  - Molecular, Pathological, Radiological, and Immune Profiling of Non-brainstem Pediatric High-Grade Glioma from the HERBY Phase II Randomized Trial.
JO  - Cancer cell
VL  - 33
IS  - 5
SN  - 1535-6108
CY  - Cambridge, Mass.
PB  - Cell Press
M1  - DKFZ-2018-00623
SP  - 829 - 842.e5
PY  - 2018
AB  - The HERBY trial was a phase II open-label, randomized, multicenter trial evaluating bevacizumab (BEV) in addition to temozolomide/radiotherapy in patients with newly diagnosed non-brainstem high-grade glioma (HGG) between the ages of 3 and 18 years. We carried out comprehensive molecular analysis integrated with pathology, radiology, and immune profiling. In post-hoc subgroup analysis, hypermutator tumors (mismatch repair deficiency and somatic POLE/POLD1 mutations) and those biologically resembling pleomorphic xanthoastrocytoma ([PXA]-like, driven by BRAF_V600E or NF1 mutation) had significantly more CD8+ tumor-infiltrating lymphocytes, and longer survival with the addition of BEV. Histone H3 subgroups (hemispheric G34R/V and midline K27M) had a worse outcome and were immune cold. Future clinical trials will need to take into account the diversity represented by the term 'HGG' in the pediatric population.
LB  - PUB:(DE-HGF)16
C6  - pmid:29763623
C2  - pmc:PMC5956280
DO  - DOI:10.1016/j.ccell.2018.04.004
UR  - https://inrepo02.dkfz.de/record/134833
ER  -